The notices it replaced
- Reissues: PAR-18-947 Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
- 2 steps back: PAR-16-166 Integrating Biospecimen Science into Clinical Assay Development (U01)
Replaced by PAR-25-325.
Who won it before
24 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $8,714,151 in first-year total cost, median $368,144.
Most frequent study sections
- Special Emphasis Panel[ZCA1 RPRB-8 (M2)]3
- Special Emphasis Panel[ZCA1 RPRB-N (J2)]3
- Special Emphasis Panel[ZCA1 RTRB-4 (M1)]2
- Special Emphasis Panel[ZCA1 RTRB-U (J1)]2
- Special Emphasis Panel[ZCA1 SRB-5 (J1)]2
Most frequent institutions
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO3
- SLOAN-KETTERING INST CAN RESEARCH2
- UNIVERSITY OF WASHINGTON2
- BARUCH S. BLUMBERG INSTITUTE1
- BRIGHAM AND WOMEN'S HOSPITAL1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Optimizing pre-analytical variables for reliable mass spectrometry-based quantification of immunomodulatory proteins in cerebrospinal fluid in pediatric neuro-oncology trials1U01CA295226-01 | PAULOVICH, AMANDA G | FRED HUTCHINSON CANCER CENTER, WA | $440,171 | ZCA1 |
| 2025 | Preanalytical Validation of Circulating Tumor DNA from Surgical Drain Fluid as a marker of Postoperative Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma1U01CA301249-01 | CHAUDHURI, AADELZEVALLOS, JOSE P. | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $360,643 | ZCA1 |
| 2025 | Impact of preanalytical conditions on functional cancer biomarkers1U01CA288665-01A1 | BHOLA, PATRICK | HARVARD MEDICAL SCHOOL, MA | $1 | ZCA1 |
| 2024 | MetaboCore: Needle biopsy assay of drug sensitivity for solid tumors.1U01CA281433-01A1 | WEI, WEIYEUNG, RAYMOND | UNIVERSITY OF WASHINGTON, WA | $401,113 | ZCA1 |
| 2024 | Enrichment for Tumor-derived Cell-free EBV DNA: Towards a Diagnostic Assay for Endemic Burkitt Lymphoma1U01CA271252-01A1 | AMBINDER, RICHARD FREDERICKXIAN, RENA | JOHNS HOPKINS UNIVERSITY, MD | $357,595 | ZCA1 |
| 2024 | Guidelines for processing and storing liquid biopsy samples for functional assays in research and clinical testing.1U01CA288669-01 | TOGNON, CRISTINA EVU, TOTHU Q | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $356,850 | ZCA1 |
| 2024 | The impact of oxygen exposure on clinical biomarkers - an underrecognized source of pre-analytic variability1U01CA278865-01A1 | MILLER, KATHY D.NAKSHATRI, HARIKRISHNA | INDIANA UNIVERSITY INDIANAPOLIS, IN | $355,980 | ZCA1 |
| 2023 | Impact of preanalytic procurement and processing variables on the detection of HCC DNA in urine1U01CA275648-01 | SU, YING-HSIU | BARUCH S. BLUMBERG INSTITUTE, PA | $395,418 | ZCA1 |
| 2023 | Comprehensive Analysis of Best Practices for Clinical Testing of Malignant Pleural Effusion Specimens1U01CA275514-01A1 | DEVINE, WALTER PATRICKKHANAFSHAR, ELHAMVAN ZIFFLE, JESSICA | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $369,431 | ZCA1 |
| 2023 | Evaluation of Pre-Analytical Factors of Urine Samples for Urine Cancer Cell Cultures (UCCC) --A Non-Invasive Biomarker – in Monitoring Response and Recurrence of Bladder Cancer1U01CA278927-01 | LIU, XUEFENG | OHIO STATE UNIVERSITY, OH | $360,281 | ZCA1 |
| 2023 | Advancing the Clinical Translation of Cyst Fluid Assays for Early Detection of Pancreatic Cancer1U01CA271250-01A1 | KIRKWOOD, KIMBERLY SAUNDERS | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $359,302 | ZCA1 |
| 2022 | Optimization of peripheral blood mononuclear cell (PBMC) processing for robust downstream functional immune cell analysis and correlation with therapeutic efficacy1U01CA267985-01 · under PAR-18-947 | DILLEHAY MCKILLIP, KELSEYWISE-DRAPER, TRISHA M | UNIVERSITY OF CINCINNATI, OH | $353,556 | ZCA1 |
| 2022 | Prostate Needle Biopsies: Impact of Preanalytical Procurement and Processing Variables on the Detection of Gene Expression Signatures of Prostate Cancer Aggressiveness1U01CA271400-01 · under PAR-18-947 | GASTON, SANDRA MPOLLACK, ALANSTOYANOVA, RADKA | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $351,131 | ZCA1 |
| 2022 | Evaluation of Patient Factors and Sample Pre-Analytics on Predictive Multiplex Immunohistochemical Assays in Immuno-Oncology Patients1U01CA263986-01A1 · under PAR-18-947 | ROEHRL, MICHAEL H. A. | SLOAN-KETTERING INST CAN RESEARCH, NY | $201,286 | ZCA1 |
| 2021 | Optimization of urinary DNA deep sequencing tests to enhance clinical staging of bladder cancer patients1U01CA260369-01 · under PAR-18-947 | ABBOSH, PHILIP | RESEARCH INST OF FOX CHASE CAN CTR, PA | $422,346 | ZCA1 |
| 2021 | Robust assays to define telomere maintenance mechanisms as cancer biomarkers.1U01CA263988-01 · under PAR-18-947 | REYNOLDS, CHARLES PATRICK | TEXAS TECH UNIVERSITY HEALTH SCIS CENTER, TX | $412,718 | ZCA1 |
| 2021 | Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signatures1U01CA253218-01A1 · under PAR-18-947 | CHAN, WING C.IQBAL, JAVEEDMURTAZA, MUHAMMED | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $391,146 | ZCA1 |
| 2020 | Liquid biopsy of the lung to profile lung cancer1U01CA253166-01 · under PAR-18-947 | HOUGHTON, A MCGARRYNAIR, VISWAM SIVA | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $427,888 | ZCA1 |
| 2020 | Optimizing pre-analytic sample handling for high throughput TCR sequencing in cutaneous T cell lymphoma1U01CA253190-01 · under PAR-18-947 | CLARK, RACHAEL ANN | BRIGHAM AND WOMEN'S HOSPITAL, MA | $422,791 | ZCA1 |
| 2020 | Influence of Pre-Analytical Factors in Globlastoma MGMT Promoter Methylation Biomarker Assay1U01CA246503-01A1 · under PAR-18-947 | BOMSZTYK, KAROLROSTOMILY, ROBERT C | UNIVERSITY OF WASHINGTON, WA | $414,577 | ZCA1 |
| 2020 | Evaluation of the effect of patient-context factors and sample acquisition on the quality and analytical performance of cell-free DNA and circulating tumor cells profiling assays in prostate cancer pa1U01CA253217-01 · under PAR-18-947 | ARCILA, MARIA ESCHER, HOWARD I | SLOAN-KETTERING INST CAN RESEARCH, NY | $404,888 | ZCA1 |
| 2019 | Pre-analytical factors affecting ctDNA analysis in early and locally advanced breast cancer1U01CA243078-01A1 · under PAR-18-947 | MURTAZA, MUHAMMED | TRANSLATIONAL GENOMICS RESEARCH INST, AZ | $440,008 | ZCA1 |
| 2019 | Mitigation of preanalytic factors influencing brain tumor protein phosphorylation1U01CA229345-01A1 · under PAR-16-166 | PHILLIPS, JOANNA | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $366,857 | ZCA1 |
| 2017 | Integrating Biospecimen Science Into The Development Of RNA-Based Clinical Assays For Patients With Metastatic Breast Cancer1U01CA215547-01 · under PAR-16-166 | SYMMANS, WILLIAM F | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $348,174 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.